Abstract |
This study in 12 cancer treatment centres across the United States was designed to evaluate the potential for increased resistance to amikacin with unrestricted use. An initial 3-month baseline period during which the use of amikacin was restricted and that of tobramycin and gentamicin unrestricted was followed by a period of at least 12 months when amikacin was the primary aminoglycoside. Resistance of Gram-negative bacilli to these aminoglycosides from hospitalized patients was monitored and compared for the two periods. Amikacin usage increased from a mean of 20.1% to a mean of 83.9% of aminoglycoside patient-days. A reduction in the use of tobramycin and gentamicin were observed with means of 66.1 and 10%, and 13.9 and 6.1%, respectively for the two periods. Resistance to amikacin was 0.85% at baseline and 1.3% at end-point which was not clinically significant (P = 0.614). Baseline resistance was 6.5 and 7.6%, while final resistance was 2.6 and 4.8%, respectively for tobramycin (P = 0.001) and gentamicin (P = 0.052).
|
Authors | J J Muscato, D W Wilbur, J J Stout, R A Fahrlender |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 27 Suppl C
Pg. 1-7
(May 1991)
ISSN: 0305-7453 [Print] England |
PMID | 1906860
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gentamicins
- Amikacin
- Tobramycin
|
Topics |
- Acinetobacter
(drug effects)
- Amikacin
(administration & dosage, pharmacology)
- Cancer Care Facilities
- Drug Resistance, Microbial
- Drug Utilization
- Enterobacteriaceae
(drug effects)
- Gentamicins
(administration & dosage, pharmacology)
- Gram-Negative Bacteria
(drug effects)
- Humans
- Prospective Studies
- Pseudomonas aeruginosa
(drug effects)
- R Factors
- Tobramycin
(administration & dosage, pharmacology)
|